Dr David Sidney Pounds, PHD PSYCHOLOGIST | |
42111 Rd 415, Coarsegold, CA 93614-1600 | |
(559) 683-3365 | |
Not Available |
Full Name | Dr David Sidney Pounds |
---|---|
Gender | Male |
Speciality | Clinical Psychologist |
Experience | 37 Years |
Location | 42111 Rd 415, Coarsegold, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154460970 | NPI | - | NPPES |
PSY124090 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103T00000X | Psychologist | PSY12409 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr David Sidney Pounds, PHD PSYCHOLOGIST Po Box 1600, Coarsegold, CA 93614-1600 Ph: (559) 683-3365 | Dr David Sidney Pounds, PHD PSYCHOLOGIST 42111 Rd 415, Coarsegold, CA 93614-1600 Ph: (559) 683-3365 |
News Archive
The University of Alicante has developed, together with centres in the UK, Spain and Bulgaria, a tool designed to assist people with autism spectrum disorders by adapting written documents into a format that is easier for them to read and understand. This is the main result of the three-year project FIRST (A Flexible Interactive Reading Support Tool), funded by the European Commission under the Seventh Framework Programme.
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).
Women with depression in the perinatal period experience a high degree of conflict in deciding whether and how to treat their depression, but strongly prefer treatments other than antidepressant medications, reports a study in the November Journal of Psychiatric Practice®. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Genentech, a member of the Roche Group, today announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated chronic lymphocytic leukemia (CLL).
Researchers at Mayo Clinic in Florida have found that a molecule long believed to be a beneficial tumor suppressor and thus a potential cancer drug target appears to act as an oncogene in some lethal brain tumors.
› Verified 7 days ago
Dr. George Samuel Laird Jr., PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 37068 Mudge Ranch Rd, Coarsegold, CA 93614 Phone: 559-683-2166 |